## Note
nid: 1527699957454
model: AnKingOverhaul
tags: #AK_Original_Decks::Step_2::Cheesy_Dorian_(M3), #AK_Step1_v11::#OME_banner::Clinical::12_Psychiatry, #AK_Step1_v11::#Physeo::09_Pharm::13_Psychiatric::16_Atypical_Antipsychotics, #AK_Step1_v11::#UWorld::10000-99999::15000-15999::15254, #AK_Step2_v11::!FLAG_THESE_CARDS::Potential_duplicates, #AK_Step2_v11::!Shelf::#Cards_AnKing_Skipped, #AK_Step2_v11::#OME::12_Psychiatry::07_Psychosis, #AK_Step2_v11::#Resources_by_rotation::Psych::uworld::dorian, #AK_Step2_v11::#Subjects::Psychiatry::07_Psychotic_Disorders::Schizophrenia, #AK_Step2_v11::#Subjects::Psychiatry::07_Psychotic_Disorders::Schizophrenia::Management::First_Line, #AK_Step2_v11::Original_decks::Dorian::psych::uw
markdown: false

### Text
What is the <i>first-line treatment</i> for <b>anti-psychotic
treatment</b> in patients with <u>schizophrenia</u>?
<div>
  {{c1::Atypical antipsychotics (<i>olanzapine, resperidone,
  quetiapine</i>)}}
</div>

### Extra
<div>
  <i>Second-generation antipsychotics antagonize both
  <b>5-HT<sub>2A</sub> and D<sub>2</sub> receptors</b>, which
  results in <u>effective treatment of psychosis</u> with a
  <u>lower risk of side effects</u></i>
</div><i>Acute psychotic episodes = short-acting (olanzapine)</i>
<div>
  <i>Poor adherence = first-generation depot</i>
</div>
<div>
  <i>Treatment resistance = clozapine</i>
</div>

### Lecture Notes


### Missed Questions


### Pathoma


### Boards and Beyond


### First Aid


### Sketchy


### Pixorize


### Physeo


### OME
<div class="ome-widget">
  <a href=
  "https://onlinemeded.org/spa/psychiatry?ref=anki"><img src=
  "_OME_AnkiFlashcards_Topic_6.png"></a>
</div>

### Additional Resources


### One by one

